Research Article
Treatment of Glucocorticoid-Induced Osteoporosis and Risk Factors for New Vertebral Fractures in Female Patients with Autoimmune Diseases
Table 1
Participant characteristics.
| | | Total (n = 90) |
| | Age (years), mean (SD) | 52.9 ± 14.5 | | Sex, female (%) | 90 (100) |
| | Underlying diseases, no. (%) | | SLE | 36 (40.0) | | Inflammatory myopathy | 14 (15.5) | | Scleroderma | 9 (10) | | MCTD | 8 (8.9) | | Sjogren’s syndrome | 5 (5.6) | | Vasculitis | 6 (6.7) | | Others | 12 (13.3) |
| | Current glucocorticoid dose, no. (%) | | <5 mg/day | 27 (30) | | 5 ≤ x < 7.5 mg/day | 36 (40) | | ≥7.5 mg/day | 27 (30) | | Prior fragility fracture (s), no. (%) | 11 (12.2) |
| | BMD (% YAM), mean (SD) | | Lumbar spine | 95.7 (12.7) | | Femoral neck | 87 (12) |
| | Glucocorticoid-induced osteoporosis score, lumbar BMD | | <3, no. (%) | 33 (37) | | 3–5, no. (%) | 25 (28) | | ≥6, no. (%) | 32 (36) |
| | Glucocorticoid-induced osteoporosis score, femoral neck BMD | | <3, no. (%) | 30 (34) | | 3–5, no. (%) | 23 (26) | | ≥6, no. (%) | 37 (40) |
|
|
SLE, systemic lupus erythematosus; MCTD, mixed connective tissue disease; YAM, young adult mean. Glucocorticoid-induced osteoporosis scores were determined as described previously [ 7]. |
